Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE | Zendy

Brian J. Werth | Zendy; Katie E. Barber | Zendy; Nikki Tran | Zendy; Poochit juie | Zendy; George Sakoulas | Zendy; Joe Pogliano | Zendy; Michael J. Rybak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE

Author(s) -

Brian J. Werth,

Katie E. Barber,

Nikki Tran,

Poochit juie,

George Sakoulas,

Joe Pogliano,

Michael J. Rybak

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku386

Subject(s) - daptomycin , ampicillin , medicine , microbiology and biotechnology , antibiotics , vancomycin , biology , staphylococcus aureus , bacteria , genetics

The synergistic combination of daptomycin plus ampicillin has proven to be effective against VRE including daptomycin-non-susceptible strains. Ceftobiprole is a cephalosporin with broad binding affinity for enterococcal PBP subtypes including PBP5. Given the synergy between β-lactams and daptomycin against VRE, it was of interest to determine whether ceftobiprole offered any synergistic advantage with daptomycin compared with ampicillin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research